On August 20, 2025 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City (Press release, TuHURA Biosciences, AUG 20, 2025, https://tuhurabio.com/tuhura-biosciences-inc-to-present-at-the-27th-annual-h-c-wainwright-global-investment-conference/ [SID1234655407]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences, is scheduled to present an overview and will be available for one-on-one meetings, as follows:

27th Annual H.C. Wainwright Global Investment Conference

Date:

Monday, September 8, 2025

Time:

2:30 PM Eastern Time

Link:

Click Here

A replay of the presentation will be available on the Events page of the Investors section of the Company’s website (tuhurabio.com). For more information about the event, please visit the conference website.